Attenuated poliovirus
A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2a CD155 tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.
1. A recombinant poliovirus containing a single active cis-acting replication element (cre element), said cre element located in the spacer region of the 5′-NTR between the cloverleaf and internal ribosome entry site (IRES), and an A 133 G mutation in domain II of the internal ribosome (IRES), wherein the cre element is an essential RNA replication element for the recombinant poiovirus, the presence of which results n viral attenuation and wherein the identified nucleotide position corresponds with that as in poliovirus type 1 (Mahoney) (PV1(M)). entry site (IRES).
2. The recombinant poliovirus of claim 1 , which comprises SEQ ID NO:1.
3. A recombinant poliovirus containing a single active cis-acting replication element (cre element) inserted at nucleotide 102/103 in the spacer region of the 5′-NTR between the cloverleaf and internal ribosome site (IRES), wherein the cre element is an essential RNA replication element for the recombinant poliovirus, the presence of which results in viral attenuation and wherein the nucleotide position corresponds with that in poliovirus type 1 (Mahoney) (PV1(M)).
4. The recombinant poliovirus of claim 3 , wherein the cre element is positioned as in SEQ ID NO:1.
5. The recombinant poliovirus of claim 1 , which comprises an inactivated native cre element in the 2C coding region of the poliovirus genome.
6. The recombinant poliovirus of claim 1 , which elicits an antitumor immune response.
7. A composition comprising a recombinant poliovirus selected from the recombinant polio virus of claim 1 or the recombinant polio virus of claim 3 , and a pharmaceutically acceptable carrier.
8. A composition according to claim 7 , wherein the composition is infusible.
9. A composition according to claim 7 , wherein the composition is injectable.
10. A composition according to claim 7 , wherein the pharmaceutically acceptable carrier is a physiological salt solution.
11. A composition according to claim 10 , wherein the physiological salt solution is HANKS balanced salt solution.
12. A kit comprising the recombinant poliovirus of claim 1 or the recombinant poliovirus of claim 3 , and instructional material for the use thereof.
13. The recombinant poliovirus of claim 3 , which comprises an inactivated native cre element in the 2C coding region of the poliovirus genome.
14. The recombinant poliovirus of claim 3 , which elicits an antitumor immune response.
15. The recombinant poliovirus of claim 1 , wherein the cre element is a cre element from a picornavirus selected from the group consisting of a poliovirus type 1, a poliovirus type 3, a human rhinovirus, and a cardiovirus.
16. The recombinant poliovirus of claim 1 , wherein the cre element is inserted at nucleotide 102/103, and wherein the cre element is the same as the native cre element of poliovirus PV1(M), and wherein the recombinant poliovirus further comprises an inactivated native cre element in the 2C coding region of the poliovirus genome.
17. The recombinant poliovirus of claim 3 , wherein the cre element is a cre element from a picornavirus selected from the groups consisting of a poliovirus type 1, a poliovirus type 3, a human rhinovirus, and a cardiovirus.
18. The recombinant poliovirus of claim 1 , wherein the cre element comprises a stem-loop structure mapping to the coding region of viral protein 2C ATPase in native poliovirus.
19. The recombinant poliovirus of claim 3 , wherein the cre element comprises a stem-loop structure mapping to the coding region of viral protein 2C ATPase in native poliovirus.